Hypothalamic hamartoma (HH), composed of neurons and glia without apparent cytologic abnormalities, is a rare developmental malformation in humans. Patients with HH often have characteristic medically refractory gelastic seizures, and intrinsic epileptogenesis within the lesions has been speculated. Herein we provide evidence to suggest that in HH neurons, Ca 2+ permeability through a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors is aberrantly elevated. In needle biopsy specimens of HH tissue, field potential recordings demonstrated spontaneous epileptiform activities similar to those observed in other etiologically distinct epileptogenic tissues. In HH, however, these activities were clearly abolished by application of Joro Spider Toxin (JSTX), a specific inhibitor of the Ca 2+ -permeable AMPA receptor. Consistent with these physiologic findings, the neuronal nuclei showed disappearance of adenosine deaminase acting on RNA 2 (ADAR2) immunoreactivity. Furthermore, examination of glutamate receptor 2 (GluA2) messenger RNA (mRNA) revealed that editing efficiency at the glutamine/arginine site was significantly low. These results suggest that neurons in HH may bear Ca 2+ -permeable AMPA receptors due to dislocation of ADAR2.
Hypothalamic hamartoma (HH) is a rare developmental malformation in humans that arises from the region of the cinereum and ventral hypothalamus. Affected patients often have characteristic medically refractory gelastic seizures, and most show associated progressive cognitive and behavioral disturbances. Several clinical studies have suggested that HH is intrinsically epileptogenic [1] [2] [3] ; however, the pathophysiologic mechanisms underlying HH remain to be elucidated. Histopathologic studies of HH have failed to demonstrate apparent abnormalities in neuronal and glial morphology, but the distribution of these cells is abnormal in certain cases. 4 Therefore, it is conceivable that alteration of the neuronal network and synaptic functions within HH may be responsible for the epileptogenesis.
The a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor is a cardinal excitatory receptor in the mammalian central nervous system, and it usually does not permit entry of Ca 2+ ions. This low permeability to Ca 2+ ions is strictly regulated by editing of glutamate receptor 2 (GluA2) messenger RNA (mRNA) at the glutamine/ arginine (Q/R) site by adenosine deaminase acting on RNA 2 (ADAR2) 5 ( Fig. S1A ,B, left of both panels). Therefore, failure of this mechanism would render AMPA receptors permeable to Ca 2+ ions, resulting in abnormal hyperexcitability under various pathologic conditions in humans, 6 as well as in several animal models of epilepsy. 7 Previously we reported that surgically resected specimens of epileptogenic foci taken from patients with etiologically disparate epileptic syndromes demonstrated common, characteristic epileptogenic activities in vitro, 8 which were apparently distinct from those evident in control tissues. 9 In the present study, using biopsied specimens taken from patients with HH, we carried out field potential recordings in vitro, and also immunohistochemical and biochemical analyses, to investigate the intrinsic epileptogenic mechanisms that were occurring.
Methods
All patients provided written informed consent, and the study was performed with the approval of the ethics committees of the University of Niigata and Nishi-Niigata Chuo National Hospital. The specimens taken from the patients were assigned to highest-priority histopathologic examination.
Patients and clinical features of HH
We used biopsy specimens taken from 11 patients with HH for local field potential (LFP) recordings in vitro (Table S1 , cases 1-11). Magnetic resonance imaging (MRI) studies of all the patients revealed tumorous lesions, 15-34 mm in diameter, either involving the hypothalamus or lying beneath it. All patients had severe daily intractable gelastic seizures. We detected frequent spikes from inside the tumorous lesions by semi-microelectrode recordings made during surgery, and performed stereotactic radiofrequency thermocoagulation (SRT) of the lesions. 1, 3 As a disease control, we also used three tissue samples of focal cortical dysplasia (FCD) resected from patients with frontal lobe epilepsy (cases [12] [13] [14] and, as a normal control, two samples of apparently normal cortical tissue resected from patients who had brain tumors but no symptoms of epilepsy (cases 15 and 16).
Field potential recordings
Needle-biopsied specimens taken from the SRT tracts were immediately immersed in ice-cold artificial cerebrospinal fluid (ACSF) bubbled with 95% O 2 and 5% CO 2 . The specimens were brought to our laboratory within 45 min after sampling, and then slices 500 lm thick were prepared using a Vibratome (Linear Slicer, Dosaka, Kyoto, Japan) as reported previously. 8, 9 LFPs were recorded through Teflon-coated tungsten electrodes (1 MΩ) at 10,000 Hz. The signals were amplified 10,000 times with an amplifier (MEG-2100, Nihon Kohden, Tokyo, Japan) and passed through a 5-10 kHz band-pass filter. Spontaneous field potentials were recorded during 30 min, and the signals were input to a computer via an analog-digital converter (PowerLab; AD Instruments) for later analyses. To construct an interevent interval (IEI) histogram, 30-min field potential recordings were band-pass filtered (5-300 Hz) and cut-off at the threshold level (50 lV). As a control tissue, we used apparently "normal" frontal or parietal cortex resected to expedite removal of deep-seated brain tumors (cases 15 and 16), who had no history of epileptic episodes before surgery. We confirmed histopathologically that the resected tissues had neither invasion of tumor cells nor any significant alterations. In some experiments, we bath-applied Joro Spider Toxin (JSTX; Wako, Tokyo, Japan) dissolved in water.
Immunohistochemistry
Another specimen taken from almost the same position in the SRT tract was fixed with 20% buffered formalin and embedded in paraffin. Sections (4 µm in thickness) were then cut and immunostained with rabbit polyclonal antibody against glial fibrillary acidic protein (GFAP) (diluted 1:4,000, Z0334; Dako, U.S.A.) or glutamate receptor 2 (diluted 1:500, 11994-1-AP; Proteintech, U.S.A.), or with mouse monoclonal antibody against neuronal nuclei (NeuN) (diluted 1:200, MAB377; Millipore, U.S.A.) or ADAR2 (diluted 1:100, sc-73049; Santa Cruz Biotechnology, U.S.A.). As a control, we also used autopsied hypothalamic tissues taken from three patients without any history of epilepsy (Table S2) .
Analysis of RNA editing and RNA quantification
Tissue samples were immersed in RNA stabilization reagent (RNAlater; Qiagen) immediately after removal in the operating room, and kept at À80°C until use. For later RNA analysis, we prepared six fresh-frozen samples of HH (cases 5-10) and two samples of FCD (cases 12 and 13). We omitted two cases of HH (cases 9 and 10) because histologic examination revealed a paucity of neurons. As a control tissue, we also used apparently normal cortical tissue from the anterior temporal lobe of patients with mesial temporal lobe epilepsy. These tissues showed no epileptogenic activities in electrocorticography (ECoG) recordings and no obvious histopathologic changes. To determine the editing efficiency at the Q/R site of GluA2 mRNAs, quantitative analysis of BbvI (New England BioLabs) digests of the reverse transcription polymerase chain reaction (RT-PCR) products was performed on total RNA extracted from the biopsy specimen. 10 The PCR products originating from Q/R siteedited GluA2 mRNA had one intrinsic restriction enzyme recognition site, whereas those originating from unedited mRNA had an additional recognition site. Thus restriction digestion of the PCR products originating from edited GluA2 mRNA would theoretically produce two bands at 68 and 202 bp, whereas those from unedited GluA2 mRNA would produce bands at 68, 81, and 121 bp. Therefore, we quantified the molarity of the 81-, 121-, and 202-bp bands (2100 Bioanalyzer; Agilent Technologies) and calculated their ratio as the editing efficiency. In addition, we performed quantitative PCR for quantification of ADAR2 mRNA in the b-actin base, as described previously. 6 Details of the procedures used for field potential recording and RNA analysis are provided in Data S1.
Results
Small pieces of the specimens (about 2 mm 3 ) were biopsied from the needle tract before SRT. Pathologic examinations revealed a small number of irregularly distributed neurons and a much larger number of diffuse glial cells, being consistent with the features of HH (Fig. S2) . These neurons were usually small without apparent morphologic abnormalities. There were no atypical large cells, including balloon cells or dysmorphic neurons that are observed in FCD type II. At >1 year after surgery, all of the patients were free from intractable gelastic seizures.
LFP recordings in vitro revealed spontaneous epileptiform activities in 8 of 11 HH cases (Table S1 ). In the remaining three cases where only a few neurons were present in the small specimens, we failed to detect neuronal activities. These epileptiform activities seemed to be similar to those detectable in FCD, in contrast to human normal cortical tissues where spontaneous activities were seldom evident (Fig. 1A) . 9 However, the regularity of the interevent intervals (IEIs), but not the amplitude, was significantly different from that in FCD (Fig. 1B,C ; p < 0.05, Kolmogorov-Smirnov test). Furthermore, these epileptiform activities in HH were significantly abolished by bath application of 10 lM JSTX (p < 0.01, paired ttest; Fig. 1D,E) , a specific inhibitor of the Ca 2+ -permeable AMPA receptor, 11 although no such effect was observed in FCD tissues. The effect of JSTX lasted for 30 min during application of the drug. These findings suggested that HH has intrinsic epileptogenic activity, consistent with evidence based on clinical observation, and may contain unusual Ca 2+ -permeable AMPA receptors. Therefore, we examined the expression of GluA2 and ADAR2 using immunohistochemistry.
We evaluated the presence of GluA2 using an antibody that recognizes the C-terminus of the GluA2 subunit, which is not part of the target site for ADAR2 editing. GluA2 immunoreactivity (IR) was diffusely present in the neuronal cell body in HH, similar to that seen in the normal hypothalamus in autopsied controls and in FCD tissue used as the biopsy control ( Fig. 2A, left panels) . In contrast to this feature, ADAR2-IR in HH was different from that in control tissues. In both normal hypothalamus and FCD, ADAR2-IR was distributed homogeneously in the nuclei of all neurons, regardless of their size and shape, consistent with the fact that ADAR2 is a nuclear enzyme 12 ( Fig. 2A right, middle and lower panels). On the other hand, in HH, IR was often undetectable in the neuronal nuclei, but distributed rather characteristically in the nucleolus and nuclear membrane, and also faintly in the cell body ( Fig. 2A right, upper panel) . In relation to this feature, we quantified the editing efficiency at the Q/R site of GluA2 mRNA in cases 5-8, and found that it was 100% in both the controls and FCD lesions, consistent with previous reports, 6,7 whereas in HH it was significantly lower (p < 0.05, Mann-Whitney U-test) (Fig. 2B,C) . The ADAR2 mRNA level in HH also tended to be lower, but not to a significant degree. Of interest, Q/R site editing efficiency was exponentially correlated with the spontaneous activities revealed in LFP recordings (Fig. 2D) .
Discussion
In the present study, both pharmacologic and biochemical data indicated abnormality of the Ca 2+ -permeable AMPA receptors in HH. Our HH patients tended to be younger than FCD patients at the time of surgery (4.0 AE 10.6 year vs. 24 AE 7.4 year, median AE standard deviation [SD] ). This may be because HH patients usually underwent surgery as soon as the diagnosis had been established, not only because of the severity of their seizures but also their accompanying cognitive and behavioral disorders. 1 We cannot exclude the possibility that the difference in lesion location between HH and FCD (hypothalamus vs. frontal cortex) might have affected the properties of the LFP activity (Fig. 1A-C) . However, this would not account for the specific sensitivity of HH to JSTX (Fig. 1D,E) , because normal neurons in mammals are not usually affected by JSTX, irrespective of their brain location. An age-dependent decrease of GluA2 expression in vivo might also be considered. 13 This appears to have been a limitation of the present study, because it is impossible to compare the expression of GluA2 in the human hypothalamus at various ages. Although we failed to observe any differences in the distribution of GluA2-IR in Table S1 (B, D). Epilepsia ILAE the hypothalamus of autopsied patients at various ages (data not shown), other sensitive methods for protein quantification would be necessary to evaluate accurately the level of GluA2 expression in the hypothalamus.
Although any AMPA receptor lacking the GluA2 subunit would also show Ca 2+ permeability, 14 this would seem unlikely in HH because the distribution of GluA2-IR was normal ( Fig. 2A, left panels) . Rather, it is conceivable that the abnormal Ca 2+ permeability might be due to dislocation of the ADAR2, although we could not exclude the possibility that another type of Ca 2+ -permeable channel, such as a voltage-gated Ca 2+ channel, was also upregulated simultaneously. It has been reported that failure of GluA2 RNA editing hardly occurs in normal mammalian neurons, 5, 10 including those in the human brain, 6, 15 as was demonstrated in our controls. Thus, HH shows significantly low editing efficiency, and this may be responsible for the dysfunction of ADAR2. Although the decrease in the Q/R site editing efficiency of GluA2 was <10% (Fig. 2B,C) , the changes were exponentially correlated with LFP activity (Fig. 2D) . Therefore, it is conceivable that these relatively small changes might sufficiently contribute to seizure susceptibility in HH patients, consistent with results of previous studies using animal models. 16 It has been reported that null mutation of ADAR2 in mice causes severe seizure status leading to early death, 7 although in the present study we found no significant decrease in the level of ADAR2 mRNA. Because HH tissue shows a heterogeneous distribution of neurons and glia, variations of these components might affect the levels of mRNA for ADAR2 and b-actin.
Our observations revealed that HH has unique physiologic and biochemical features, including the activity pattern, sensitivity to JSTX (Fig. 1) , and presence of neuronal ADAR2-IR (Fig. 2) , being indicative of characteristic underlying epileptogenic mechanisms. Thus failure of GluA2 editing due to dislocation of ADAR2 results in glutamate-triggered Ca 2+ influx, followed by neuronal hyperexcitability. This information may be informative for development of a new therapeutic strategy for patients with HH and gelastic seizures.
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